Instil Bio presents CoStAR platform data at SITC; ITIL-306 Phase 1 ongoing

Instil Bio, Inc.

Pre-clinical data showed CoStAR amplified T-cell responses across all FRα expression levels, supporting clinical exploration in multiple solid tumors.
First patient dosed in ITIL-306 Phase 1 study in October 2022; evaluating safety and feasibility in advanced solid tumors.
Treatment regimen is free of high-dose interleukin-2.
Posters presented at SITC 2022; available on company website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.